The price you pay for Gilenya may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the cost of ...
If you have multiple sclerosis (MS), your doctor may prescribe Gilenya for you. It’s used in certain people with MS. MS is a condition that affects communication between your brain and spinal cord, ...
Basel, May 11, 2018 - Novartis today announced that the US Food and Drug Administration (FDA) has approved Gilenya® (fingolimod) for the treatment of children and adolescents 10 to less than 18 years ...
The digital press release with multimedia content can be accessed here: Basel, September 16, 2016 - Novartis today announced new data from the ACROSS study, which assessed 10-year disability outcomes ...
EAST HANOVER, N.J., May 30, 2013 /PRNewswire/ -- People with relapsing multiple sclerosis (MS) reported greater treatment satisfaction after starting the oral treatment Gilenya ® (fingolimod) vs.
Novartis lost an appeal to protect a 2026 patent on multiple sclerosis blockbuster Gilenya, which brought in more than $3 billion last year. Novartis' bid to fend off early Gilenya generics has failed ...
Novartis got a reprieve last week when the U.S. Patent and Trademark Office upheld a patent on its multiple sclerosis blockbuster Gilenya. Now, the Swiss pharma intends to use that win in court ...
EAST HANOVER, N.J., April 11, 2011 /PRNewswire/ -- A new analysis demonstrated that Gilenya™ (fingolimod) reduced the risk of disability progression in patients with relapsing-remitting multiple ...
EMA has issued a recommendation that the multiple sclerosis drug, Gilenya (fingolimod), not be used in women who are pregnant. The European Medicines Agency (EMA) has issued a recommendation that the ...
Mississippi awarded more than $104 million in federal rural health grants across 167 projects. Where the money goes and why rural access matters. Rural Virginia Paramedics Make Home Visits to Cut ...
In Apotex Inc. v. Novartis AG, IPR2017-00854, Paper 109 (Jul. 11, 2018), the PTAB held that the claims of U.S. Patent No. 9,187,405 were not unpatentable on three separate grounds. Shortly thereafter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results